In vitro activity of CEM-102 (Fusidic Acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4535-4536

  Sahm, D F ^a   Deane, J ^a   Pillar, C M ^b   Fernandes, P ^c  

^a Eurofins Medinet Inc   (Germany)

^b Micromyx   (United States)

^c Cempra Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FUSIDATE SODIUM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; FUSIDIC ACID; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; STAPHYLOCOCCUS AUREUS;

EID: 84882338030     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00206-13     Document Type: Article

References (17)

1. Casey AL, Lambert PA, Elliot TS. 2007. Staphylococci. Int. J. Antimicrob. Agents 29(Suppl 3):S23-S32.
2. Morales G, Picazo JJ, Baso E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sanchez-Garcia M. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50:821-825.
3. Sakoulas G, Moellering RC, Jr. 2008. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin. Infect. Dis. 46(Suppl 5):S360-S367.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oquri T, Tenover FC. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
5. CDC. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:565-567.
6. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. 2005. Development of daptomycin resistance in vivo in methicillinresistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
7. Brown EM, Thomas P. 2002. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 359:803.
8. O'Neil AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. 2007. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J. Clin. Microbiol. 45:1505-1510.
9. O'Neill AJ, McLaws F, Kahlmeter G, Henriksen AS, Chopra I. 2007. Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob. Agents Chemother. 51:1737-1740.
10. Castanheira M, Walters AA, Bell JM, Turnidge JD, Jones RN. 2010. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob. Agents Chemother. 54:3614-3617.
11. Jones RN, Mendes RE, Sader HS, Castanheira M. 2011. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clin. Infect. Dis. 52(Suppl 7):S477-S486.
12. Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernades P. 2011. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin. Infect. Dis. 52(Suppl 7):S520-S526.
13. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. 2011. Application of pharmacokineticpharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin. Infect. Dis. 52(Suppl 7):S513-S519.
14. CLSI. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document M7-A8. CLSI, Wayne, PA.
15. CLSI. 2010. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S20. CLSI, Wayne, PA.
16. EUCAST. 2011. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3, March. EUCAST, Basel, Switzerland. http://www.eucast. org/clinical-breakpoints.
17. Pfaller MA, Castanheira M, Sader HS, Jones RN. 2010. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int. J. Antimicrob. Agents 35:282-287.